Stock Price Quote

ASPIRA PATHLAB & DIAGNOSTICS LTD.

NSE : NABSE : 540788ISIN CODE : INE500C01017Industry : Hospital & Healthcare ServicesHouse : Private
BSE34.00-0.55 (-1.59 %)
PREV CLOSE ( ) 34.55
OPEN PRICE ( ) 34.99
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1657
TODAY'S LOW / HIGH ( )34.00 35.00
52 WK LOW / HIGH ( ) 22.7649.5
NSE
This Company is not listed in NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 03-07 1973
Management Info
Haseeb Drabu - Chairman Pankaj Shah - Managing Director
Registered Office

Address Flat No. 2, R D Shah Building,Shraddanand Road, Opp. Ghatkopar Railway Station,Ghatkopar (West),
Mumbai,
Maharashtra-400086

Phone 022-7197 5756 / 2513 9090

Email info@aspiradiagnostics.com / support@aspiradiagnostics.com

Website www.aspiradiagnostics.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,L B S Marg,Vikhroli (West),Mumbai
Listing : BSE

NEWS

28Dec Aspira Pathlab & Diagnostics informs a
Aspira Pathlab & Diagnostics has informed that pursuant to the Secur..
13Nov Aspira Pathlab & Diagnostics informs a
Pursuant to regulation 47 of the Securities and Exchange Board of India..
12Aug Aspira Pathlab & Diagnostics informs a
Aspira Pathlab & Diagnostics has informed about Appointment of Mr. M..
24Jun Aspira Pathlab & Diagnostics informs a
Pursuant to Regulation 30 of the Securities and Exchange Board of India..
24Jun Aspira Pathlab & Diagnostics informs a
Pursuant to Regulation 30 of the Securities and Exchange Board of India..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit-7.42000000000001-0.879999999999994
Gross Profit -7.42000000000001 -0.879999999999994
Operating Profit -2.7200000000000119.15
Net Sales 34.62144.57

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Global Health (BSE)
peergroup  1488.15 (4.34%)
M.Cap ( in Cr)39949.00
Dr Agarwals Eye Hsp (BSE)
peergroup  3380.40 (0.84%)
M.Cap ( in Cr)1588.79
Dr. Lal Pathlabs (BSE)
peergroup  2446.50 (0.79%)
M.Cap ( in Cr)20422.86
Narayana Hrudayalay (BSE)
peergroup  1370.80 (1.33%)
M.Cap ( in Cr)28013.78
Metropolis Health. (BSE)
peergroup  1749.45 (1.03%)
M.Cap ( in Cr)8961.88

Shareholding Pattern

NON-INSTITUTION 81.1%
PROMOTERS 18.9%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Aspira Pathlab & Diagnostics Ltd.

Aspira Pathlab & Diagnostics Ltd. was incorporated in the year 1973. Its today's share price is 34. Its current market capitalisation stands at Rs 35 Cr. In the latest quarter, company has reported Gross Sales of Rs. 144.57 Cr and Total Income of Rs.147.78 Cr. The company's management includes Krupali Shah, Manas Mengar, Nikunj Mange, Subhash Raghunath Salunke, Mangala Prabhu, Avinash Chander Mahajan, Arvind K Bhanushali, Haseeb Drabu, Pankaj Shah.

It is listed on the BSE with a BSE Code of 540788 , NSE with an NSE Symbol of and ISIN of INE500C01017. It's Registered office is at Flat No. 2, R D Shah Building,Shraddanand Road, Opp. Ghatkopar Railway Station,Ghatkopar (West)Mumbai-400086, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are P Khetan & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.